Payment overview · 2025
General Payments
$1,884.71
30 reported records · 17 companies
Healthcare provider profile · identity verified
Ayaz A Malik, MD
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · SAINT LOUIS, MO · NPI 1518992429
Verified facts
What the public records show
CMS Open Payments records show Ayaz A Malik, MD received $1,884.71 in general payments during 2025 across 30 reported records.
Endologix LLC accounted for 43.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Endologix LLC | Unresolved — no canonical attribution shown | $810.99 | 43.0% | 5 | 2025 |
| Shape Memory Medical Inc. | Unresolved — no canonical attribution shown | $233.51 | 12.4% | 2 | 2025 |
| Bolton Medical Inc | Unresolved — no canonical attribution shown | $214.34 | 11.4% | 2 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $161.55 | 8.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$151.40 | 8.0% | 6 | 2025 |
| TriSalus Life Sciences, Inc. | Unresolved — no canonical attribution shown | $44.65 | 2.4% | 1 | 2025 |
| CashFlow Solutions, LLC | Unresolved — no canonical attribution shown | $34.80 | 1.9% | 2 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $33.57 | 1.8% | 2 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $27.71 | 1.5% | 1 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $25.69 | 1.4% | 1 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $25.53 | 1.4% | 1 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $21.67 | 1.1% | 1 | 2025 |
| LeMaitre Vascular, Inc. | Unresolved — no canonical attribution shown | $21.55 | 1.1% | 1 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $20.68 | 1.1% | 1 | 2025 |
| Neuros Medical, Inc. | Unresolved — no canonical attribution shown | $19.90 | 1.1% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $19.02 | 1.0% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $18.15 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,884.71 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $475.55 | 2 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $475.55 | 2 | 2025 |
Source payment records
|
|||||
| Alto Abdominal Stent Graft System Normalized: alto abdominal stent graft system |
Device | Endologix LLC | $254.10 | 2 | 2025 |
Source payment records
|
|||||
| IMPEDE EMBOLIZATION PLUG Normalized: impede embolization plug |
Device | Shape Memory Medical Inc. | $233.51 | 2 | 2025 |
Source payment records
|
|||||
| TREO ABDOMINAL STENT-GRAFT SYSTEM Normalized: treo abdominal stent graft system |
Device | Bolton Medical Inc | $214.34 | 2 | 2025 |
Source payment records
|
|||||
| LUTONIX Drug Coated Balloon Normalized: lutonix drug coated balloon |
Device | Bard Peripheral Vascular, Inc. | $161.55 | 1 | 2025 |
Source payment records
|
|||||
| CLOSUREFAST Normalized: closurefast |
Device | Medtronic, Inc. | $99.13 | 3 | 2025 |
Source payment records
|
|||||
| AFX2 Bifurcated Endograft System Normalized: afx2 bifurcated endograft system |
Device | Endologix LLC | $81.34 | 1 | 2025 |
Source payment records
|
|||||
| RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM Normalized: relay thoracic stent graft with plus delivery system |
Device | Bolton Medical Inc | $68.90 | 1 | 2025 |
Source payment records
|
|||||
| THORAFLEX HYBRID Normalized: thoraflex hybrid |
Device | Bolton Medical Inc | $68.90 | 1 | 2025 |
Source payment records
|
|||||
| TRINAV INFUSION SYSTEM Normalized: trinav infusion system |
Device | TriSalus Life Sciences, Inc. | $44.65 | 1 | 2025 |
Source payment records
|
|||||
| LYMPHA PRESS OPTIMAL PLUS(US) BT Normalized: lympha press optimal plus us bt |
Device | CashFlow Solutions, LLC | $34.80 | 2 | 2025 |
Source payment records
|
|||||
| PCD-51 731A (US) - White Normalized: pcd 51 731a us white |
Device | CashFlow Solutions, LLC | $34.80 | 2 | 2025 |
Source payment records
|
|||||
| PCD-52 737A (US) White Normalized: pcd 52 737a us white |
Device | CashFlow Solutions, LLC | $34.80 | 2 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $27.71 | 1 | 2025 |
Source payment records
|
|||||
| HELI-FX ENDOANCHOR SYSTEM Normalized: heli fx endoanchor system |
Device | Medtronic, Inc. | $26.69 | 1 | 2025 |
Source payment records
|
|||||
| ACTIV.A.C. Normalized: activ a c |
Device | Solventum Corporation | $25.69 | 1 | 2025 |
Source payment records
|
|||||
| V.A.C.INSTILL Normalized: v a c instill |
Device | Solventum Corporation | $25.69 | 1 | 2025 |
Source payment records
|
|||||
| IN.PACT ADMIRAL Normalized: in pact admiral |
Device | Medtronic, Inc. | $25.58 | 2 | 2025 |
Source payment records
|
|||||
| ATRICLIP LAA EXCLUSION SYSTEM Normalized: atriclip laa exclusion system |
Device | AtriCure, Inc. | $25.53 | 1 | 2025 |
Source payment records
|
|||||
| ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM Normalized: atricure cryoice cryosphere cryoablation system |
Device | AtriCure, Inc. | $25.53 | 1 | 2025 |
Source payment records
|
|||||
| AtriCure cryoICE Cryoablation System (CRYO2) Normalized: atricure cryoice cryoablation system cryo2 |
Device | AtriCure, Inc. | $25.53 | 1 | 2025 |
Source payment records
|
|||||
| SYNERGY ABLATION SYSTEM Normalized: synergy ablation system |
Device | AtriCure, Inc. | $25.53 | 1 | 2025 |
Source payment records
|
|||||
| AZUR CX DETACHABLE Normalized: azur cx detachable |
Device | Terumo Medical Corporation | $21.67 | 1 | 2025 |
Source payment records
|
|||||
| HYDRO LEMAITRE VALVULOTOME Normalized: hydro lemaitre valvulotome |
Device | LeMaitre Vascular, Inc. | $21.55 | 1 | 2025 |
Source payment records
|
|||||
| Integra Normalized: integra |
Device | Integra LifeSciences Corporation | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| Integra Dermal Regeneration Template Normalized: integra dermal regeneration template |
Device | Integra LifeSciences Corporation | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| PRIMATRIX Normalized: primatrix |
Device | Integra LifeSciences Corporation | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| Altius Normalized: altius |
Device | Neuros Medical, Inc. | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| "ACTICOAT 4"" X 4""" Normalized: acticoat 4 x 4 |
Device | Smith+Nephew, Inc. | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| PICO Normalized: pico |
Device | Smith+Nephew, Inc. | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $15.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Xarelto | Rivaroxaban | 117 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 25 |
| Cilostazol | Cilostazol | 61 | 20 |
| Pentoxifylline | Pentoxifylline | 53 | 14 |
| Atorvastatin Calcium | Atorvastatin Calcium | 47 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 39 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 22 | suppressed |
| Gabapentin | Gabapentin | 21 | suppressed |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,884.71 · 30 records | Endologix LLC | "ACTICOAT 4"" X 4""", ACTIV.A.C., AFX2 Bifurcated Endograft System, ARTIX MT, ATRICLIP LAA EXCLUSION SYSTEM, ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM, AZUR CX DETACHABLE, Altius, Alto Abdominal Stent Graft System, AtriCure cryoICE Cryoablation System (CRYO2), CLOSUREFAST, COLLAGENASE SANTYL, ENDOCROSS Device, Flexitouch Plus, HELI-FX ENDOANCHOR SYSTEM, HYDRO LEMAITRE VALVULOTOME, IMPEDE EMBOLIZATION PLUG, IN.PACT ADMIRAL, Integra, Integra Dermal Regeneration Template, LUTONIX Drug Coated Balloon, LYMPHA PRESS OPTIMAL PLUS(US) BT, Nimbl, PCD-51 731A (US) - White, PCD-52 737A (US) White, PICO, PRIMATRIX, RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM, SYNERGY ABLATION SYSTEM, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, THORAFLEX HYBRID, TREO ABDOMINAL STENT-GRAFT SYSTEM, TRINAV INFUSION SYSTEM, Torus Stent Graft System, V.A.C.INSTILL | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error